The Prescrire Awards for 2012
The 2012 Prescrire Awards: a yearly round-up from the editors of independent French journal Prescrire
Prescrire looks back at new drugs and indications in 2012
Prescrire's ratings of new products and indications over the last 10 years
| Prescrire's ratings of new products and indications over the last 10 years (a) |
PRESCRIRE'S RATING
|
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
| Bravo |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
| A real advance |
4 |
0 |
1 |
1 |
2 |
0 |
0 |
1 |
0 |
1 (b) |
| Offers an advantage |
5 |
6 |
4 |
8 |
14 |
6 |
3 |
3 |
3 |
3 (c) |
| Possibly helpful |
23 |
12 |
20 |
31 |
27 |
25 |
14 |
22 |
13 |
14 |
Nothing new
|
34 |
41 |
38 |
69 |
79 |
57 |
62 |
49 |
53 |
42 |
Not acceptable
|
7 (d) |
7 |
19 |
17 |
15 |
23 |
19 |
19 |
16 |
15 (e) |
Judgement reserved
|
6 |
4 |
2 |
8 |
3 |
9 |
6 |
3 |
7 |
7 (f) |
| Total |
79 |
70 |
84 |
135 |
141 |
120 |
104 |
97 |
92 |
82 |
| |
Notes :
|
| a - The previous years' results (1988 to 2002) can be found in Prescrire Int n° 64. This table lists new products (other than generics) and new indications (including unauthorised indications) proposed in France by drug companies to doctors and pharmacists, for use in hospitals or the community; and, as of 2005, line extensions (new dose strengths, new formulations and presentations of existing drugs and products for self-medication, rated in our French edition, la revue Prescrire. A given product is counted several times if it received different ratings in different indications. |
| b- The drug was: boceprevir in chronic hepatitis C (Prescrire Int n° 126). |
c- The drugs were:
- abiraterone in prostate cancer after failure of other treatments (Prescrire Int n° 128);
- telaprevir in chronic hepatitis C (Prescrire Int n° 126);
- trastuzumab as adjuvant therapy for breast cancer after more follow-up (Prescrire Int n° 133).
|
| d- Including two jointly marketed products. |
e- The drugs were:
- asenapine in manic episodes in bipolar disorder (Prescrire Int n° 131);
- bevacizumab in metastatic breast cancer in combination with capecitabine
(Rev Prescrire n° 340);
- bevacizumab in advanced ovarian cancer (Rev Prescrire n° 348);
- domperidone in gastrointestinal disturbances (Rev Prescrire n° 340);
- fluticasone in atopic dermatitis in infants 3 months of age and older (Prescrire Int n° 129);
- insulin detemir in combination with liraglutide in type 2 diabetes (Rev Prescrire n° 348);
- ivabradine in heart failure (Rev Prescrire n° 348);
- linagliptin in type 2 diabetes (Rev Prescrire n° 347);
- pirfenidone in mild to moderate idiopathic pulmonary fibrosis (Rev Prescrire n° 350);
- roflumilast in severe chronic obstructive pulmonary disease (Prescrire Int n° 134);
- saxagliptin in type 2 diabetes in combination with insulin (Rev Prescrire n° 349);
- the saxagliptin + metformin combination in type 2 diabetes (Rev Prescrire n° 349);
- sildenafil in pulmonary arterial hypertension in children (Prescrire Int n° 129);
- vandetanib in medullary thyroid cancer (Prescrire Int n° 131);
- vernakalant in atrial fibrillation (Prescrire Int n° 127).
|
f- The drugs were:
- carglumic acid for organic acidaemia in neonates and infants (Rev Prescrire n° 349);
- brentuximab vedotin in Hodgkin's lymphoma or systemic anaplastic large cell lymphoma
(Rev Prescrire n° 349);
- ipilimumab in metastatic melanoma (Prescrire Int n° 128);
- mexiletine in myotonic syndromes (Rev Prescrire n° 344);
- ranibizumab in retinal vein occlusion (Prescrire Int n° 130);
- tafamidis in transthyretin amyloidosis (Rev Prescrire n° 349);
- vemurafenib in metastatic melanoma (Prescrire Int n° 133).
|
| ©Prescrire April 2013 |
|
"New drugs and indications in 2012. Sluggish progress, timid measures to protect patients" Prescrire Int 2013; 22 (137): 105-107. (Pdf, free)
|
| |
